Big delays with CFDA licenses. Chinese regulatory bodies are merging and no licences have been issued since Chinese next year. I'm also hearing that Organic Formula license is a crowded trade so potential reluctance for CFDA to expedite BAL license. In any case the backlog of work for CFDA to get through will likely lead to a delay for BAL. That will subsequently lead to a big FY19 earnings hole. That's my view.... DYOR
BAL Price at posting:
$18.59 Sentiment: Sell Disclosure: Not Held
